These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
352 related items for PubMed ID: 23651165
1. PPAR-gamma in ulcerative colitis: a novel target for intervention. Bertin B, Dubuquoy L, Colombel JF, Desreumaux P. Curr Drug Targets; 2013 Nov; 14(12):1501-7. PubMed ID: 23651165 [Abstract] [Full Text] [Related]
3. [A clinical trial of rosiglitazone and 5-aminosalicylate combination for ulcerative colitis]. Liang HL, Ouyang Q. Zhonghua Nei Ke Za Zhi; 2006 Jul; 45(7):548-51. PubMed ID: 17074107 [Abstract] [Full Text] [Related]
4. Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-gamma activity. Pedersen G, Brynskov J. Am J Gastroenterol; 2010 Jul; 105(7):1595-603. PubMed ID: 20087330 [Abstract] [Full Text] [Related]
5. A Novel Topical PPARγ Agonist Induces PPARγ Activity in Ulcerative Colitis Mucosa and Prevents and Reverses Inflammation in Induced Colitis Models. Da Silva S, Keita ÅV, Mohlin S, Påhlman S, Theodorou V, Påhlman I, Mattson JP, Söderholm JD. Inflamm Bowel Dis; 2018 Mar 19; 24(4):792-805. PubMed ID: 29529198 [Abstract] [Full Text] [Related]
6. [Recent trends in PPARgamma agonist development of thiazolidinediones and non-thiazolidinediones]. Tanaka T. Nihon Rinsho; 2010 Feb 19; 68(2):249-55. PubMed ID: 20158092 [Abstract] [Full Text] [Related]
7. Intestinal steroidogenesis controls PPARγ expression in the colon and is impaired during ulcerative colitis. Bouguen G, Langlois A, Djouina M, Branche J, Koriche D, Dewaeles E, Mongy A, Auwerx J, Colombel JF, Desreumaux P, Dubuquoy L, Bertin B. Gut; 2015 Jun 19; 64(6):901-10. PubMed ID: 25053717 [Abstract] [Full Text] [Related]
8. Protective Effect of Naringin on DSS-Induced Ulcerative Colitis in Mice. Cao H, Liu J, Shen P, Cai J, Han Y, Zhu K, Fu Y, Zhang N, Zhang Z, Cao Y. J Agric Food Chem; 2018 Dec 19; 66(50):13133-13140. PubMed ID: 30472831 [Abstract] [Full Text] [Related]
9. Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist. Linard C, Grémy O, Benderitter M. J Pharmacol Exp Ther; 2008 Mar 19; 324(3):911-20. PubMed ID: 18077625 [Abstract] [Full Text] [Related]
10. Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Schaefer KL, Denevich S, Ma C, Cooley SR, Nakajima A, Wada K, Schlezinger J, Sherr D, Saubermann LJ. Inflamm Bowel Dis; 2005 Mar 19; 11(3):244-52. PubMed ID: 15735430 [Abstract] [Full Text] [Related]
11. PPARγ signaling and emerging opportunities for improved therapeutics. Wang S, Dougherty EJ, Danner RL. Pharmacol Res; 2016 Sep 19; 111():76-85. PubMed ID: 27268145 [Abstract] [Full Text] [Related]
12. Rosiglitazone, a PPARgamma ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats. Sánchez-Hidalgo M, Martín AR, Villegas I, de la Lastra CA. Eur J Pharmacol; 2007 May 21; 562(3):247-58. PubMed ID: 17343846 [Abstract] [Full Text] [Related]
13. 5-Aminosalicylic Acid Ameliorates Colitis and Checks Dysbiotic Escherichia coli Expansion by Activating PPAR-γ Signaling in the Intestinal Epithelium. Cevallos SA, Lee JY, Velazquez EM, Foegeding NJ, Shelton CD, Tiffany CR, Parry BH, Stull-Lane AR, Olsan EE, Savage HP, Nguyen H, Ghanaat SS, Byndloss AJ, Agu IO, Tsolis RM, Byndloss MX, Bäumler AJ. mBio; 2021 Jan 19; 12(1):. PubMed ID: 33468700 [Abstract] [Full Text] [Related]
14. [The peroxisome-proliferator-activated gamma receptor and chronic inflammatory bowel disease (PPARgamma and IBD)]. Rousseaux C, Desreumaux P. J Soc Biol; 2006 Jan 19; 200(2):121-31. PubMed ID: 17151549 [Abstract] [Full Text] [Related]
15. 5-aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model. Ikeda I, Tomimoto A, Wada K, Fujisawa T, Fujita K, Yonemitsu K, Nozaki Y, Endo H, Takahashi H, Yoneda M, Inamori M, Kubota K, Saito S, Nagashima Y, Nakagama H, Nakajima A. Clin Cancer Res; 2007 Nov 01; 13(21):6527-31. PubMed ID: 17975166 [Abstract] [Full Text] [Related]
18. Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-α activation. Esposito G, Capoccia E, Turco F, Palumbo I, Lu J, Steardo A, Cuomo R, Sarnelli G, Steardo L. Gut; 2014 Aug 01; 63(8):1300-12. PubMed ID: 24082036 [Abstract] [Full Text] [Related]
19. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress. Cho N, Momose Y. Curr Top Med Chem; 2008 Aug 01; 8(17):1483-507. PubMed ID: 19075761 [Abstract] [Full Text] [Related]
20. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Belvisi MG, Hele DJ, Birrell MA. Eur J Pharmacol; 2006 Mar 08; 533(1-3):101-9. PubMed ID: 16458290 [Abstract] [Full Text] [Related] Page: [Next] [New Search]